Emily’s Entourage speeds lifesaving research and drug development for individuals in the final 10% of the cystic fibrosis (CF) community that do not benefit from currently available mutation-targeted therapies, including those with nonsense mutations of CF.
EE has awarded millions of dollars to multi-disciplinary teams around the world to advance research and drug development for the final 10% of people with CF.
Our cystic fibrosis clinical trial matchmaking program is direct-to-consumer, making trial recruitment faster, more targeted, and more efficient.
EE maintains a patient registry of individuals with CF who are genetically ineligible for or do not benefit from existing CFTR modulator therapies to inform them about relevant clinical trials.